Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique combination antibiotic therapy – effective against the WHO Critical Priority Carbapenem resistant bacterial pathogens
The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin.
The combination is active against all three WHO Critical Priori...
Continue Reading →
